Abstract
With the continuing and increasing popularity of the amphetamine analog 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) as a drug of abuse, concern also has increased regarding the long-term psychological and neurochemical effects of this drug. The acute psychological effects of MDMA include a mild sense of euphoria and sense of well being and increased ability to interact with others (1) which contribute to the drug’s popularity. Recent studies in laboratory animals and humans indicate that repeated exposure to MDMA elicits long-term changes in neurochemistry and behavior that are viewed as resulting from a selective neurotoxicity of 5-hydroxytryptamine (5-HT)-containing axon terminals.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Parrott, A. C. (2002) Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol. Biochem. Behav. 71, 837–844.
Nichols, D. E., Lloyd, D. H., Hoffman, A. J., Nichols, M. D., and Yim, G. K. (1982) Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptoxomes. J. Med. Chem. 25, 530–535.
Johnson, M. P., Hoffman, A. J., and Nichols, D. E. (1986) Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur. J. Pharmacol. 132, 269–276.
Gough, B., Ali, S. F., Slikker, W., Jr., and Holson, R. R. (1991) Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol. Biochem. Behav. 39, 619–623.
Gudelsky, G. A. and Nash, J. F. (1996) Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J. Neurochem. 66, 243–249.
Rudnick, G. and Wall, S. C. (1992) The molecular mechanism of “ecstasy” [3,4-methylenedioxymethamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl. Acad. Sci. USA 89, 1817–1821.
Yamamoto, B. K. and Spanos, L. J. (1988) The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur. J. Pharmacol. 148, 195–203.
Nash, J. F. and Nichols, D. E. (1991) Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues. Eur J.Pharmacol. 200, 53–58.
Nash, J. F. and Brodkin, J. (1991) Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors. J. Pharmacol. Exp. Ther. 259, 820–825.
Yamamoto, B. K., Nash, J. F., and Gudelsky, G. A. (1995) Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and γ-aminobutyric acid in the substantia nigra. J. Pharmacol. Exp. Ther. 273, 1063–1070.
Nash, J. F. (1990) Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci. 47, 2401–2408.
Gudelsky, G. A., Yamamoto, B. K., and Nash, J. F. (1994) Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 agonists. Eur. J. Pharmacol. 264, 325–330.
Schmidt, C. J., Sullivan, C. K., and Fadayel, G. M. (1994) Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J. Neurochem. 62, 1382–1389.
Fisher, H. S., Zerning, G., Schatz, D. S., Humpel, C., and Saria, A. (2000) MDMA (Ecstasy) enhances basal acetylcholine release in brain slices of the rat striatum. Eur. J. Neurosci. 12, 1385–1390.
Acquas, E., Marrocu, P., Pisanu, A., et al. (2001) Intravenous administration of ecstasy (3,4-methylenedioxymethamphetamine) enhances cortical and striatal acetylcholine release in vivo. Eur. J. Pharmacol. 418, 207–211.
Nair, S. and Gudelsky, G. A. (2002) MDMA enhances acetylcholine release in the prefrontal cortex and hippocampus of the rat. Soc. Neurosci. Abstr. No. 809.17.
Nash, J. F., Jr., Meltzer, H. Y., and Gudelsky, G. A. (1988) Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 245, 873–879.
Schmidt, C. J., Black, C. K., Abbate, G. M., and Taylor V. L. (1990) Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res. 529, 85–90.
Spanos, L. J. and Yamamoto, B. K. (1989) Acute and subchronic effects of methylenedioxymethamphetamine [(±)MDMA] on locomotion and serotonin syndrome behavior in the rat. Pharmacol. Biochem. Behav. 32, 835–840.
Shankaran, M. and Gudelsky, G. A. (1999) A neruotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration. Psychopharmacology 147, 66–72.
McCreary, A. C., Bankson, M. G., and Cunningham, K. A. (1999) Pharmacological studies of the acute and chronic effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine1A and 5-hydroxytryptamine1B/1D receptors. J. Pharmacol. Exp. Ther. 290, 965–973.
Morley, K. C. and McGregor, I. S. (2000) (±)-3,4-Methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) increases social interaction in rats. Eur. J. Pharmacol. 408, 41–49.
Schmidt, C. J. (1987) Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 240, 1–7.
Ricaurte, G. A. Forno, L., Wilson, M. A., et al. (1988) (+)-3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA 260, 51–55.
Battaglia, G., Yeh, S. Y., O’Hearn, E., Molliver, M. E., Kuhar, M., and De Souza, E. B. (1987) 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J. Pharmacol. Exp. Ther. 242, 911–921.
Stone, D. M., Stahl, D., Hanson, G. R., and Gibb, J. W. (1986) The effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoaminergic systems in rat brain. Eur. J. Pharmacol. 128, 41–49.
O’Hearn, E., Battaglia, G., De Souza, E. B., Kuhar, M. J., and Molliver, M. E. (1988) Methylenedioxyamphetamine (MDA) and methylenedioxy-methamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J. Neurosci. 8, 2788–2803.
Logan, B. J., Laverty, R., Sanderson, W. D., and Yee, Y. B. (1988) Differences between rats and mice in MDMA (methylenedioxy-methylamphetamine) neurotoxicity. Eur. J. Pharmacol. 152, 227–234.
Miller, D. B. and O’Callaghan, J. P. (1994) Environment, drug and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57B1/6J mouse. J. Pharmacol. Exp. Ther. 270, 752–760.
McCann, U., Szabo, Z., Scheffel, U., Dannais, R., and Ricaurte, G. A. (1998) Positron emission tomographic evidence of toxic effect of MDMA(Ecstasy) on brain serotonin neurons in human beings. Lancet 352, 1433–1437.
Reneman, L., Lavalaye, J., Schmand, B., et al. (2001) Cortical serotonin transport density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy). Arch. Gen. Psychiatry 58, 901–906.
Sabol, K. E., Lew, R., Richards, J. B., Vosmer, G. L., and Seiden, L. S. (1996) Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 51-week period. Part I: Synaptosomal uptake and tissue concentrations. J. Pharmacol. Exp. Ther. 276, 846–854.
Lew, R., Sabol, K. E., Chou, C., Vosmer, G. L., Richards, J., and Seiden, L. S. (1996) Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: Radioligand binding and autoradiography studies. J. Pharmacol. Exp. Ther. 276, 855–865.
Fischer, C., Hatzidimitriou, G., Wios, J., Katz, J., and Ricaurte, G. (1995 Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (±)3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”). J. Neurosci. 15, 5476–5485.
Commins, D. L., Vosmer, G., Virius, R., Woolverton, W. L., Schuster, C. R., and Seiden, L. S. (1987) Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in the rat brain. J. Pharmacol. Exp. Ther. 241, 338–344.
Scallet, A. C., Lipe, G. W., Ali, S. F., Holson, R. R., Frith, C. H., and Slikker, W., Jr. (1988) Neuropathological evaluation by combined immunohistochemistry and degeneration-specific methods: application of methylenedioxymethamphetamine. Neurotoxicology 9, 529–538.
O’Callaghan, J. P. and Miller, D. B. (1993) Quantification of reactive gliosis as an approach to neurotoxicity, in Assessing Neurotoxicity of Drugs of Abuse (Erinoff, L., ed.), NIDA Monograph 136, pp. 188–212.
Callahan, B. T., Cord, B. J., and Ricaurte, G. A. (2001) Long-term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamine. Synapse 40, 113–121.
Gudelsky, G. A., Wallace, T. L., Vorhees, C. V., and Zemlan, F. P. (2001) Methamphetamine enhances the cleavage of the cytoskeletal protein tau in the striatum and hippocampus of the rat. Soc. Neurosci. Abstr. 358.6.
Schmidt, C. J., Black, C. K., Abbate, G. M., and Taylor, V. L. (1990) Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine. Eur. J. Pharmaocol. 181, 59–70.
Aguirre, N., Barrionuevo, M., Lasheras, B., and Del Río, J. (1998) The role of dopaminergic systems in the perinatal sensitivity to 3,4-methylenedioxymethamphetamine-induced neurotoxicity in rats. J. Pharmacol. Exp. Ther. 286, 1159–1165.
Stone, D. M., Johnson, M., Hanson, G. R., and Gibb, J. W. (1988) Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 247, 79–87.
Shankaran, M., Yamamoto, B. K., and Gudelsky, G. (1999) Mazindol attenuates the 3,4-methylenedioxymethamphetamine-induced formation of hydroxyl radicals and long-term depletion of serotonin in the striatum. J. Neurochem. 72, 2516–2522.
Kanthasamy, A. and Nichols, D. E. (2002) Unilateral injection of dopamine transporter antisense oligonucleotide into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum. Soc. Neurosci. Abstr., No. 445.18.
Schmidt, C. J., Taylor, V. L., Abbate, G. M., and Nieduzak, T. R. (1991) 5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by l-dopa. J. Pharmacol. Exp. Ther. 256, 230–235.
Michel, P. P. and Hefti, F. (1990) Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J. Neurosci. Res. 26, 428–435.
Filloux, F. and Townsend, J. J. (1993) Pre-and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp. Neurol. 119, 79–88.
Sprague, J. E., Everman, S. L., and Nichols, D. E. (1998) An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylene-dioxymethamphetamine. Neurotoxicology 19, 427–442.
Johnson, M. P. and Nichols, D. E. (1991) Combined administration of a non-neurotoxic 3,4-methylenedioxymethamphetamine analogue with amphetamine produces serotonin neurotoxicity in rats. Neuropharmacology 30, 819–822.
Schmidt, C. J. and Kehne, J. H. (1990) Neurotoxicity of MDMA: neurochemical effects. Ann. NY Acad. Sci. 600, 665–680.
Shankaran, M., Yamamoto, B. K., and Gudelsky, G. A. (1999) Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine. Eur. J. Pharmacol. 385, 103–110.
Kramer, H. K., Poblete, J. C., and Azmitia, E. C. (1997) Activation of protein kinase C (PKC) by 3,4-methylenedioxymethamphetamine (MDMA) occurs through the stimulation of serotonin receptors and transporter. Neuropsychopharmacology 17, 117–129.
Molliver, M. E., O’Hearn, E., Battaglia, G., and DeSouza, E. B. (1986) Direct intracerebral administration of MDA and MDMA does not produce serotonin neurotoxicity. Soc. Neurosci. Abstr. 12, 1234.
Paris, J. M. and Cunningham, K. A. (1991) Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA). Brain Res. Bull. 28, 115–119.
Nixdorf, W. L., Burrows, K. B., Gudelsky, G. A., and Yamamoto, B. K. (2001) Enhancement of 3.4-methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate. J. Neurochem. 77, 647–654.
Esteban, B., O’Shea, E., and Camarero, J. (2001) 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology 154, 251–260.
Miller, R. T., Lau, S. S., and Monks, T. J. (1997) 2,4-bis-(Glutathion-S-yl)-α-methyldopamine, a putative metabolite of 3,4-methylenedioxy-methamphetamine, decreases brain serotonin concentrations. Eur. J. Pharmacol. 323, 173–180.
Bai, F., Jones, D. C., Lau, S. S., and Monks, T. J. (2001) Serotonergic neurotoxicity of 3,4-(±)-methylenedioxyamphetamine and 3,4-(±)-methylendioxymethamphetamine (Ecstasy) is potentiated by inhibition of γ-glutamyl transpeptidase. Chem. Res. Toxicol. 14, 863–870.
Gudelsky, G. A. (1996) Effect of ascorbate and cysteine on the 3-4-methylenedioxymethamphetamine-induced depletion of brain serotonin. J. Neural Transm. 103, 1397–1404.
Malberg, J. E. and Seiden, L. S. (1998) Small changes in ambient temperature cause large changes in 3,4-methylenedioxy-methamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J. Neurosci. 18, 5086–5094.
Darvesh, A. S., Shankaran, M., and Gudelsky, G. (2002) 3,4-methylenedioxymethamphetamine produces glycogenolysis and increases the extracellular concentration of glucose in the rat brain. J. Pharmacol. Exp. Ther. 300, 138–144.
Broening, H. W., Bowyer, J. F., and Slikker, W. Jr. (1995) Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (±)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. J. Pharmacol. Exp. Ther. 275, 325–333.
Farfel, G. M. and Seiden, L. S. (1995) Role of hyperthermia in the mechanism of protection against serotonergic toxicity. I. Experiments using 3,4-methylenedioxymethamphetamine, dixolcipine, CGS 19755 and NBQX. J. Pharmacol. Exp. Ther. 272, 860–867.
Malberg, J. E., Sabol, K. E., and Seiden, L. S. (1996) Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J. Pharamcol. Exp. Ther. 278, 258–267.
Colado, M. I., O’Shea, E., Granados, R., Murray, T. K., and Green, A. R. (1997) In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA (‘ecstasy’) and p-chloramphetamine but not the degeneration following fenfluramine. Br. J. Pharmacol. 121, 889–900.
Colado, M. I., O’Shea, E., Granados, R., Esteban, B., Martin, A. B., and Green, A. R. (1999) Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) administration. Br. J. Pharmacol. 126, 911–924.
Cadet, J. L., Ladenheim, B, Baum, I., Carlson, E., and Epstein, C. (1994) CuZn-superoxide dismutase (CuZnSOD) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (MDA) and of methylenedioxymethamphetamine (MDMA). Brain Res. 655, 259–262.
Colado, M. I., Camarero, J., Mechan, A. O., et al. (2001) A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) on dopamine neurones in mouse brain. Br. J. Pharmacol. 134, 1711–1723.
Taraska, T. and Finnegan, K. T. (1997) Nitric oxide and the neurotoxic effects of methamphetamine and 3,4-methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 280, 941–947.
Zheng, Y. and Laverty, R. (1998) Role of brain nitric oxide in (±)3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity in rats. Brain Res. 795, 257–263.
Nash, J. F. and Yamamoto, B. K. (1992) Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res. 581, 237–243.
Burrows, K. B., Gudelsky, G. A., and Yamamoto, B. K. (2000) Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4-methylenedioxymethamphetamine administration. Eur. J. Pharmacol. 398, 11–18.
Sprague, J. E. and Nichols, D. E. (1995) The monoamine oxidase-B inhibitor l-deprenyl protects against 3,4-methylenedioxy-methamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J. Pharmacol. Exp. Ther. 273, 667–673.
Colado, M. I., O’Shea, E., Ados, R., Misra, A., Murray, T. K., and Green, A. R. (1997) A study of the neurotoxic effect of MDMA (‘ecstasy’) on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy. Br. J. Pharmacol. 121, 827–833.
Shankaran, M., Yamamoto, B. K., and Gudelsky, G. A. (2001) Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT. Synapse 40, 55–64.
Colado, M. I. and Green, A. R. (1995) The spin trap reagent α-phenyl-N-tert-butyl nitrone prevents ‘ecstasy’-induced neurodegeneration of 5-hydroxytryptamine neurons. Eur. J. Pharmacol. 280, 343–346.
Yeh, S. Y. (1999) N-tert-Butyl-alpha-phenylnitrone protects against 3,4-methylenedioxymethamphetamine-induced depletion of serotonin in rats. Synapse 31, 169–177.
Chan, P., Di Monte, D., Luo, J. J., DeLaney, L. E., Irwin, I., and Langston, J. W. (1994) Rapid ATP loss caused by methamphetamine in the mouse striatum: relationship between energy impairment and dopaminergic neuroxicity. J. Neurochem. 62, 2484–2487.
Stephans, S. E., Whittingham, T. S., Douglas, A. J., Lust, W. D., and Yamamoto, B. K. (1998) Substrates of energy metabolism attenuate methamphetamine-induced neurotoxicity in striatum. J. Neurochem. 71, 613–621.
Huang, N. K., Wan, F. J., Tseng, C. J., and Tung, C. S. (1997) Nicotinamide attenuates methamphetamine-induced striatal dopamine depletion in rats. NeuroReport 8, 1883–1885.
Burrows, K. B., Nixdorf, W. L., and Yamamoto, B. K. (2000) Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines. J. Pharmacol. Exp. Ther. 292, 853–860.
Albers, D. S., Zeevalk, G., and Sonsalla, P. K. (1996) Damage to dopaminergic nerve terminals in mice by combined treatment of intrastriatal malonate with systemic methamphetamine or MPTP. Brain Res. 718, 217–220.
Huether, G., Zhou, D., and Rüther, E. (1997) Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) and its congeners. J. Neural Transm. 104, 771–794.
Poblete, J. C. and Azmitia, E. C. (1995) Activation of glycogen phosphorylase by serotonin and 3,4-methylenedioxymethamphetamine in astroglial-rich primary cultures: involvement of the 5-HT2A receptor. Brain Res. 680, 9–15.
Series, H. G., Masurier, M., Gartside, S., Franklin, M., and Sharp, T. (1995) Behavioral and neuroendocrine responses to d-fenfluramine in rats treated with neurotoxic amphetamines. J. Psychopharmacol. 9, 214–219.
Bauman, M. H., Ayestas, M., and Rothman, R. B. (1998) Functional consequences of central serotonin depletion produced by repeated fenfluramine administration to rats. J. Neurosci. 18, 9069–9077.
Poland, R. E., Lutchmansingh, P., McCracken, J. T., et al. (1997) Abnormal ACTH and prolactin responses to fenfluramine in rats exposed to single and multiple doses of MDMA. Psychopharmacology 131, 411–419.
Gartside, S., McQuade, R., and Sharp, T. (1996) Effects of repeated administration of 3,4-methylenedioxymethamphetamine on 5-hydroxytryptamine neuronal activity and release in the rat brain in vivo. J. Pharmacol. Exp. Ther. 279, 277–283.
Aguirre, N., Frechilla, D., García-Osta, A., Lasheras, B., and Del Río, J. (1997) Differential regulation by methylenedioxymethamphetamine of 5-hydroxytryptamine1A receptor density and mRNA expression in rat hippocampus, frontal cortex, and brainstem: the role of corticosteroids. J. Neurochem. 68, 1099–1105.
Aguirre, N., Ballaz, S., Lasheras, B., and Del Río, J. (1998) MDMA (‘Ecstasy’) enhances 5-HT1A receptor density and 8-OH-DPAT-induced hypothermia: blockade by drugs preventing 5-hydroxytryptamine depletion. Eur. J. Pharmacol. 346, 181–188.
Wallace, T. L., Gudelsky, G., and Vorhees, C. V. (2001) Alterations in diurnal and nocturnal locomotor activity in rats treated with a monoamine-depleting regimen of methamphetamine or 3,4-methylenedioxymethamphetamine. Psychopharmacology 153, 321–326.
Dafters, R. I. and Lynch, E. (1998) Persistent loss of thermoregulation in the rat induced by 3,4-methylenedioxymethamphetamine (MDMA or “Ecstasy”) but not by fenfluramine. Psychopharmacology 138, 207–212.
Mechan, A. O., O’Shea, E., Elliott, J. M., Colado, M. I., and Green, A. R. (2001) A neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) to rats results in a long term defect in thermoregulation. Psychopharmacology 155, 413–418.
Matuszewich, L., Filon, M. E., Finn, D. A., and Yamamoto, B. K. (2002) Altered forebrain neurotransmitter responses to immobilization stress following 3,4-methylenedioxymethamphetamine. Neuroscience 110, 41–48.
Jones, B. E. (2000) Basic mechanisms of sleep-wake state, in Principles and Practice of Sleep Medicine, 3rd ed. (Kryger, M. H., Roth, T., and Dement, W. C., eds.), W. B. Saunders, Philadelphia, pp. 134–154.
Morley, K. C., Gallate, J. E., Hunt, G. E., Mallet, P. E., and McGregor, I. S. (2001) Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine (“Ecstasy”). Eur. J. Pharmacol. 433, 91–99.
Mechan, A., Moran, P., Elliott, J. M., Young, A., Joseph, M. H., and Green, A. R. (2002) A study of the effect of a single neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) on the subsequent long-term behaviour of rats in the plus maze and open field. Psychopharmacology 159, 167–175.
Fone, K. C. F., Beckett, S. R. G., Topham, I. A., Swettenham, J., Ball, M., and Maddocks, L. (2002) Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. Psychopharmacology 159, 437–444.
Broening, H. W., Morford, L. L., Inman-Wood, S. L., Fukumura, M., and Vorhees, C. V. (2001) 3,4-Methylenedioxymethamphetamine (Ecstasy)-induced learning and memory impairments depend on the age of exposure during early development. J. Neurosci. 21, 3228–3235.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Gudelsky, G.A., Yamamoto, B.K. (2003). Neuropharmacology and Neurotoxicity of 3,4-Methylenedioxymethamphetamine. In: Wang, J.Q. (eds) Drugs of Abuse. Methods In Molecular Medicine™, vol 79. Humana Press. https://doi.org/10.1385/1-59259-358-5:55
Download citation
DOI: https://doi.org/10.1385/1-59259-358-5:55
Publisher Name: Humana Press
Print ISBN: 978-1-58829-057-1
Online ISBN: 978-1-59259-358-3
eBook Packages: Springer Protocols